Raphael Pharmaceutical (RAPH) Cash from Operations (2020 - 2025)
Raphael Pharmaceutical's (RAPH) quarterly Cash from Operations came in at $46000.0 in Q4 2025, up 174.19% year-over-year from $16776.5 in Q4 2024, and up 370.59% quarter-over-quarter from -$17000.0 in Q3 2025.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Cash from Operations (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical has disclosed Cash from Operations across 6 years of filings, most recently posting $46000.0 for Q4 2025.
- In Q4 2025, Cash from Operations rose 174.19% year-over-year to $46000.0; the TTM figure through Dec 2025 stood at -$210000.0 (up 60.53% YoY), while the FY2025 annual figure was -$210000.0, up 60.53% from the prior year.
- Cash from Operations came in at $46000.0 for Q4 2025 at Raphael Pharmaceutical, up from -$17000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of $46000.0 in Q4 2025 to a low of -$704000.0 in Q4 2021.
- Average Cash from Operations over 5 years is -$206150.0, with a median of -$190500.0 recorded in 2024.
- Year-over-year, Cash from Operations sank 386.59% in 2023 and jumped 174.19% in 2025.
- Over 5 years, Cash from Operations stood at -$704000.0 in 2021, then surged by 60.65% to -$277000.0 in 2022, then jumped by 68.23% to -$88000.0 in 2023, then grew by 29.55% to -$62000.0 in 2024, then surged by 174.19% to $46000.0 in 2025.
- Per Business Quant data, the three most recent Cash from Operations figures were $46000.0 in Q4 2025, -$17000.0 in Q3 2025, and -$30000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 4.00 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 3.57 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.13 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 813.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -526.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 448.90 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -270.50 Mn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Mar 31, 2025 | -209,000.00 |
| Dec 31, 2024 | -62,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Jun 30, 2024 | -218,000.00 |
| Mar 31, 2024 | -172,000.00 |
| Dec 31, 2023 | -88,000.00 |
| Sep 30, 2023 | -501,000.00 |
| Jun 30, 2023 | -215,000.00 |
| Mar 31, 2023 | -399,000.00 |
| Dec 31, 2022 | -277,000.00 |
| Sep 30, 2022 | -152,000.00 |
| Jun 30, 2022 | -248,000.00 |
| Mar 31, 2022 | -82,000.00 |
| Dec 31, 2021 | -704,000.00 |
| Sep 30, 2021 | -281,000.00 |
| Jun 30, 2021 | -305,000.00 |
| Mar 31, 2021 | -129,000.00 |